MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
TSX:MDP • CA58410Q2036
2.88 CAD
0 (0%)
Last: Feb 27, 2026, 07:00 PM
MDP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. MDP has an average financial health and profitability rating. MDP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year MDP has reported negative net income.
- In the past year MDP had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
- In multiple years MDP reported negative operating cash flow during the last 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -0.18%, MDP is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
- The Return On Equity of MDP (-0.52%) is better than 66.67% of its industry peers.
- MDP has a better Return On Invested Capital (3.02%) than 72.73% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MDP is in line with the industry average of 8.25%.
- The 3 year average ROIC (9.89%) for MDP is well above the current ROIC(3.02%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROIC | 3.02% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
- MDP has a better Operating Margin (3.91%) than 75.76% of its industry peers.
- MDP has a Gross Margin of 53.87%. This is amongst the best in the industry. MDP outperforms 81.82% of its industry peers.
- MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDP is still creating some value.
- MDP has more shares outstanding than it did 1 year ago.
- MDP has more shares outstanding than it did 5 years ago.
- MDP has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 0.62, we must say that MDP is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.62, MDP is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
- MDP has a debt to FCF ratio of 1.48. This is a very positive value and a sign of high solvency as it would only need 1.48 years to pay back of all of its debts.
- MDP has a Debt to FCF ratio of 1.48. This is amongst the best in the industry. MDP outperforms 90.91% of its industry peers.
- A Debt/Equity ratio of 0.35 indicates that MDP is not too dependend on debt financing.
- MDP has a Debt to Equity ratio (0.35) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Altman-Z | 0.62 |
ROIC/WACC0.33
WACC9.3%
2.3 Liquidity
- A Current Ratio of 1.12 indicates that MDP should not have too much problems paying its short term obligations.
- MDP has a Current ratio of 1.12. This is in the lower half of the industry: MDP underperforms 78.79% of its industry peers.
- MDP has a Quick Ratio of 1.12. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- MDP's Quick ratio of 0.62 is on the low side compared to the rest of the industry. MDP is outperformed by 78.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 |
3. Growth
3.1 Past
- MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -112.14%.
- Looking at the last year, MDP shows a decrease in Revenue. The Revenue has decreased by -9.23% in the last year.
- MDP shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.82% yearly.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
3.2 Future
- Based on estimates for the next years, MDP will show a very strong growth in Earnings Per Share. The EPS will grow by 53.29% on average per year.
- MDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.22% yearly.
EPS Next Y-188.37%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue Next Year-8.56%
Revenue Next 2Y3.98%
Revenue Next 3Y7.5%
Revenue Next 5Y11.22%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MDP. In the last year negative earnings were reported.
- The Price/Forward Earnings ratio is 10.43, which indicates a very decent valuation of MDP.
- Based on the Price/Forward Earnings ratio, MDP is valued cheaply inside the industry as 84.85% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 28.05. MDP is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.43 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MDP is valued cheaply inside the industry as 84.85% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 93.94% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.98 | ||
| EV/EBITDA | 5.78 |
4.3 Compensation for Growth
- MDP's earnings are expected to grow with 77.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.9%
EPS Next 3Y77.1%
5. Dividend
5.1 Amount
- No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MDP (2/27/2026, 7:00:00 PM)
2.88
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2026-02-11/amc
Earnings (Next)N/A N/A
Inst Owners3.25%
Inst Owner ChangeN/A
Ins Owners7.59%
Ins Owner ChangeN/A
Market Cap93.37M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target7.03 (144.1%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)10.94%
PT rev (3m)11.47%
EPS NQ rev (1m)50%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)-460%
Revenue NQ rev (1m)0.82%
Revenue NQ rev (3m)1.21%
Revenue NY rev (1m)-0.52%
Revenue NY rev (3m)-2.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.43 | ||
| P/S | 0.69 | ||
| P/FCF | 3.98 | ||
| P/OCF | 3.93 | ||
| P/B | 1.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.78 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.28
Fwd EY9.59%
FCF(TTM)0.72
FCFY25.12%
OCF(TTM)0.73
OCFY25.42%
SpS4.19
BVpS2.2
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROCE | 4.2% | ||
| ROIC | 3.02% | ||
| ROICexc | 3.61% | ||
| ROICexgc | 107.26% | ||
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% | ||
| FCFM | 17.26% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 2.1% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 1.57 | ||
| Cash Conversion | 127.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | 0.62 |
F-Score5
WACC9.3%
ROIC/WACC0.33
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-188.37%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.56%
Revenue Next 2Y3.98%
Revenue Next 3Y7.5%
Revenue Next 5Y11.22%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.75%
EBIT Next 3Y62.94%
EBIT Next 5Y48.64%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.
What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.